
Title:
Sotrovimab
Text:
Monoclonal antibody



.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}SotrovimabMonoclonal antibodyTypeWhole antibodySourceHumanTargetSpike protein of SARS-CoV-2Clinical dataTrade namesXevudyOther namesVIR-7831, GSK4182136AHFS/Drugs.comMultum Consumer InformationLicense data
EU EMA: by INN
US DailyMed: Sotrovimab
Pregnancycategory
AU: B2[1]

Routes ofadministrationIntravenousATC codeNoneLegal statusLegal status
AU: S4 (Prescription only) [1][2][3]
UK: POM (Prescription only) [4]
US: ℞-only via emergency use authorization [5]
EU: Rx-only [6]
IdentifiersCAS Number2423014-07-5IUPHAR/BPS11333DrugBankDB16355UNII1MTK0BPN8VKEGGD12014
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2.[6][7][8] It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.[7][9] Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.[7][8][10]
The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.[6]

Contents

1 Medical uses
2 Development and mechanism of action

2.1 Clinical efficacy


3 Manufacturing
4 Society and culture

4.1 Economics
4.2 Legal status


5 Research
6 References
7 External links



Medical uses[edit]
In the European Union, sotrovimab is indicated for the treatment of COVID-19 in people aged twelve years of age and older and weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.[6]

Development and mechanism of action[edit]
Sotrovimab's development began in December 2019 at Vir Biotechnology in San Francisco, when Vir scientists first learned of the initial COVID-19 outbreak in China.[11]  Vir subsidiary Humabs BioMed had already compiled a library of frozen blood samples from patients infected with viral diseases, including two samples from patients infected with SARS-CoV-1.[11]  Vir scientists obtained samples of the novel SARS-CoV-2 virus and mixed them with the old SARS-CoV-1 blood samples.[11]  The objective was to identify antibodies effective against both SARS-CoV-1 and SARS-CoV-2.[11]  This would imply that the antibodies were targeting highly conserved sequences and thus, such antibodies would be more likely to remain active against future variants of SARS-CoV-2.[11]  In April 2020, Lawrence Berkeley National Laboratory conducted a X-ray crystallography study at Vir's request to investigate how such antibodies bind to SARS-CoV-2 at the molecular level.[11]  The Berkeley Lab data helped Vir identify candidates for further study, and Vir settled on a single candidate, S309.[11]  Vir collaborated with GlaxoSmithKline to make various refinements to S309, resulting in sotrovimab.[11] 
Sotrovimab has been engineered to possess an Fc LS mutation (M428L/N434S) that confers enhanced binding to the neonatal Fc receptor[12] resulting in an extended half-life and potentially enhanced drug distribution to the lungs.[13]
Sotrovimab has demonstrated activity via two antiviral mechanisms in vitro, antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).[13]

Clinical efficacy[edit]
The pivotal COMET-ICE study is an ongoing, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of sotrovimab in adults with confirmed COVID-19 (mild, early disease with less than five days of symptoms) at risk of disease progression.
An interim analysis of this study reported that sotrovimab reduced the risk of hospitalization for more than 24 hours or death by 85% compared with placebo. Overall 1% of people receiving sotrovimab died or required hospitalization for more than 24 hours compared to 7% of people treated with placebo.[8] The study is ongoing and preliminary results have been published in the New England Journal of Medicine.[14]

Manufacturing[edit]
Sotrovimab is a biologic product which takes six months to manufacture in living cells.[11] At product launch in May 2021, sotrovimab's active pharmaceutical ingredient was produced by WuXi Biologics in China and sent to a GlaxoSmithKline plant in Parma, Italy for further processing.[15]  In January 2022, the spread of the SARS-CoV-2 Omicron variant began to render other monoclonal antibodies obsolete and caused global demand for sotrovimab to skyrocket.[15]  In response, Vir and GlaxoSmithKline announced they were working with Samsung Biologics on manufacturing sotrovimab at an additional site in South Korea.[15] 

Society and culture[edit]
Economics[edit]
In 2021, the United States government agreed to purchase 1.5 million doses of the drug at $2,100 per dose.[16]

Legal status[edit]
On 21 May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) completed its review on the use of sotrovimab for the treatment of COVID‑19. It concluded that sotrovimab can be used to treat confirmed COVID-19 in adults and adolescents (aged twelve years and above and weighing at least 40 kilograms (88 lb)) who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19.[8] On 16 December 2021, the CHMP recommended authorizing sotrovimab for use in the EU[6][17] and authorization was granted the next day.[6][18]
On 26 May 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for sotrovimab for the treatment of mild-to-moderate COVID-19 in people aged aged twelve years and above weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.[19][20][21][22]
In August 2021, sotrovimab was granted provisional approval for the treatment of COVID-19 in Australia.[2]
On 27 September 2021, sotrovimab was granted special exception authorization in Japan.[23]
In December 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom approved sotrovimab for use in people aged twelve years of age and over who weigh more than 40 kilograms (88 lb).[24][25][4]

Research[edit]
Sotrovimab is being evaluated in the following clinical trials:[13]

Clinical trial number NCT04545060 for "COMET-ICE" at ClinicalTrials.gov
Clinical trial number NCT04779879 for "COMET-PEAK" at ClinicalTrials.gov
Clinical trial number NCT04501978 for "ACTIV-3-TICO" at ClinicalTrials.gov
Clinical trial number NCT04634409 for "BLAZE-4" at ClinicalTrials.gov
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Xevudy". Therapeutic Goods Administration (TGA). 20 August 2021. Retrieved 17 September 2021.

^ Jump up to: a b "TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA) (Press release). 20 August 2021. Retrieved 4 September 2021.

^ "COVID-19 treatment: GlaxoSmithKline Australia Pty Ltd, sotrovimab (Xevudy)". Therapeutic Goods Administration (TGA). 20 August 2021. Retrieved 22 October 2021.

^ Jump up to: a b "Regulatory approval of Xevudy (sotrovimab)". Medicines and Healthcare products Regulatory Agency (MHRA). 2 December 2021. Retrieved 24 December 2021.

^ "Sotrovimab injection, solution, concentrate". DailyMed. Retrieved 15 June 2021.

^ Jump up to: a b c d e f "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Retrieved 17 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

^ Jump up to: a b c "EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19". European Medicines Agency (EMA) (Press release). 7 May 2021. Retrieved 21 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

^ Jump up to: a b c d "EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19". European Medicines Agency (EMA) (Press release). 21 May 2021. Retrieved 21 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

^ "GSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19". GlaxoSmithKline (Press release). 7 May 2021. Retrieved 21 May 2021.

^ "EMA starts review of VIR-7831 for treating patients with COVID-19". European Medicines Agency (EMA) (Press release). 15 April 2021. Retrieved 21 May 2021.

^ Jump up to: a b c d e f g h i Krieger, Lisa M. (23 January 2022). "How one person's cells led to our only antibody treatment for omicron". The Mercury News. Retrieved 24 January 2022.

^ Saunders KO (2019). "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life". Frontiers in Immunology. 10: 1296. doi:10.3389/fimmu.2019.01296. PMC 6568213. PMID 31231397.

^ Jump up to: a b c "Assessment Report: Use of sotrovimab for the treatment of COVID-19" (PDF). European Medicines Agency. May 2021.

^ Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR,  et al. (November 2021). "Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab". The New England Journal of Medicine. 385 (21): 1941–1950. doi:10.1056/NEJMoa2107934. PMID 34706189. S2CID 240074048.

^ Jump up to: a b c Roland, Denise (21 January 2022). "GlaxoSmithKline Racing to Provide Only Effective Covid-19 Antibody Treatment". The Wall Street Journal. Retrieved 24 January 2022.

^ "After slow start, demand for COVID monoclonal antibodies treatment skyrockets". USA Today. 25 August 2021. Retrieved 18 December 2021.

^ "COVID-19: EMA recommends authorisation of antibody medicine Xevudy" (Press release). 16 December 2021.

^ "Xevudy". Union Register of medicinal products. Retrieved 24 December 2021.

^ "Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 26 May 2021. Retrieved 26 May 2021.  This article incorporates text from this source, which is in the public domain.

^ "Emergency Use Authorization 100: Sotrovimab". U.S. Food and Drug Administration (FDA). 28 May 2021.

^ "Fact Sheet for Healthcare Providers Emergency Use Authorization (Eua) of Sotrovimab". U.S. Food and Drug Administration (FDA). 2021.

^ "Frequently Asked Questions on the Emergency Use Authorization of Sotrovimab". U.S. Food and Drug Administration (FDA). 26 May 2021.

^ "GSK Received Approval for Monoclonal Antibody, "Xevudy for Intravenous Injection" (generic name: sotrovimab), for the treatment of COVID-19" (PDF) (Press release). 27 September 2021. Retrieved 1 January 2022.

^ "UK approves another antibody treatment for Covid". BBC News Online. 2 December 2021. Retrieved 2 December 2021.

^ "MHRA approves Xevudy (sotrovimab), a COVID-19 treatment found to cut hospitalisation and death by 79%". Medicines and Healthcare products Regulatory Agency (MHRA) (Press release). 2 December 2021. Retrieved 24 December 2021.


External links[edit]
"Sotrovimab". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT04545060 for "VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)" at ClinicalTrials.gov
Australian Public Assessment Report: Sotrovimab. Therapeutic Goods Administration (TGA) (Report). 20 August 2021.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteMonoclonal antibodies for infectious disease and toxinsFungalHuman
Efungumab†
ViralHuman
Ansuvimab
Atoltivimab (+maftivimab/odesivimab)
Bamlanivimab† (+etesevimab)†
Casirivimab† (+imdevimab)
Cilgavimab† (+tixagevimab)†
Diridavumab§
Etesevimab†
Exbivirumab§
Foravirumab§
Imdevimab† (+casirivimab)
Libivirumab§
Maftivimab
Odesivimab
Rafivirumab§
Regavirumab§
Regdanvimab
Sevirumab†
Sotrovimab
Suptavumab
Tixagevimab† (+cilgavimab)†
Tuvirumab§
Nirsevimab†
Chimeric
Cosfroviximab
Larcaviximab
Porgaviximab
Humanized
Felvizumab§
Lenvervimab†
Motavizumab†
Palivizumab
Suvizumab§
BacterialHuman
Nebacumab
Panobacumab§
Raxibacumab
Mouse
Edobacomab§
Chimeric
Pagibaximab†
Humanized
Tefibazumab†
ToxinHuman
Actoxumab§
Bezlotoxumab
Suvratoxumab
Chimeric
Obiltoxaximab
Humanized
Urtoxazumab§

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteCOVID-19 pandemic
COVID-19 (disease)
SARS-CoV-2 (virus)
TimelinePre-pandemic
Severe acute respiratory syndrome (SARS)
Middle East respiratory syndrome (MERS)
Crimson Contagion
Disease X
Event 201
Exercise Cygnus
2019
2020
January
responses
February
responses
March
responses
April
responses
May
responses
June
responses
July
responses
August
responses
September
responses
October
responses
November
responses
December
responses
2021
January
responses
February
responses
March
responses
April
responses
May
responses
June
responses
July
responses
August
responses
September
responses
October
responses
November
responses
December
responses
Omicron variant
2022
January
responses
LocationsAfrica(timelinenationalresponses)Northern
Algeria
Canary Islands
Ceuta
Egypt
Libya
Mauritania
Melilla
Morocco
Sudan
Tunisia
Western Sahara
Sahrawi Arab Democratic Republic
Eastern
Burundi
Comoros
Djibouti
Eritrea
Ethiopia
Kenya
Madagascar
Mauritius
Mayotte
Réunion
Rwanda
Seychelles
Somalia
Puntland
Somaliland
South Sudan
Tanzania
Uganda
Southern
Angola
Botswana
Eswatini
Lesotho
Malawi
Mozambique
Namibia
South Africa
List of deaths
Zambia
Zimbabwe
Central
Cameroon
Central African Republic
Chad
Democratic Republic of the Congo
Republic of the Congo
Gabon
São Tomé and Príncipe
Western
Benin
Burkina Faso
Cape Verde
Equatorial Guinea
Gambia
Ghana
timeline
March–July 2020
August–December 2020
2021
government response
impact
education
Guinea
Guinea-Bissau
Ivory Coast
timeline
Liberia
Mali
Niger
Nigeria
timeline
February–June 2020
July–December 2020
January–June 2021
government response
Saint Helena, Ascension and Tristan da Cunha
Senegal
Sierra Leone
Togo
AsiaCentral/North
Kazakhstan
Kyrgyzstan
Russia
timeline
January–June 2020
July–December 2020
impact
economic
social
political
Tajikistan
Turkmenistan
Uzbekistan
East
Hong Kong
Japan
timeline
Tokyo 2020 Summer Olympics and Paralympics
North Korea
South Korea
Macau
Mongolia
Taiwan
respirator diplomacy
Mainland China
lockdown
detail
statistics
vaccination
Beijing
Beijing 2022 Winter Olympics and Paralympics
Heilongjiang
Henan
Hubei
Inner Mongolia
Liaoning
Shanghai
Sichuan
Tibet
Xinjiang
South
Afghanistan
timeline
Bangladesh
timeline
Bhutan
Maldives
Nepal
timeline
Pakistan
timeline
Tablighi Jamaat hotspot
Sri Lanka
India
timeline
January–May 2020
June–December 2020
2021
economic impact
evacuations
lockdown
migrant workers' crisis
union government response
PM CARES Fund
SAARC COVID-19 Emergency Fund
state government responses
vaccination
Vaccine Maitri
Statistics
Andaman and Nicobar Islands
Andhra Pradesh
Arunachal Pradesh
Assam
Bihar
Chandigarh
Chhattisgarh
Dadra and Nagar Haveli and Daman and Diu
Delhi
Tablighi Jamaat hotspot
Goa
Gujarat
Haryana
Himachal Pradesh
Jammu and Kashmir
Jharkhand
Karnataka
Kerala
timeline
Ladakh
Lakshadweep
Madhya Pradesh
Maharashtra
Manipur
Meghalaya
Mizoram
Nagaland
Odisha
Puducherry
Punjab
Rajasthan
Sikkim
Tamil Nadu
Telangana
Tripura
Uttar Pradesh
Uttarakhand
West Bengal
Southeast
Brunei
Cambodia
East Timor
Indonesia
timeline
2020
2021
social restrictions
Community Activities Restrictions Enforcement
Laos
Myanmar
Singapore
timeline
2020
2021
circuit breaker response
vaccination
statistics
Thailand
timeline
vaccination
statistics
Vietnam
timeline
government response
Malaysia
impact
social
economic
political
Aid and relief efforts
movement control order
Tablighi Jamaat COVID-19 hotspot
timeline
2020
2021
statistics
Johor
Kuala Lumpur
Sabah
Sarawak
Selangor
Philippines
timeline
2020
2021
government response
community quarantines
Luzon
evacuations
testing controversy
vaccination
Bangsamoro
Bicol Region
Cagayan Valley
Calabarzon
Caraga
Central Luzon
Central Visayas
Cordillera
Davao Region
Eastern Visayas
Ilocos Region
Metro Manila
cases
Mimaropa
Northern Mindanao
Soccsksargen
Western Visayas
Zamboanga Peninsula
Overseas Filipinos
cases
West
Armenia
Azerbaijan
Artsakh
Bahrain
Cyprus
Northern Cyprus
Egypt
Georgia
Abkhazia
South Ossetia
Iran
Iraq
Kurdistan Region
Israel
Jordan
Kuwait
Lebanon
Oman
Palestine
Qatar
Saudi Arabia
Syria
Turkey
timeline
United Arab Emirates
Yemen
EuropeUnited Kingdom
history
timeline
January–June 2020
July–December 2020
January–June 2021
July–December 2021
responses
government response
Operation Rescript
contracts
impact
social
economic
education
England
January–June 2020 timeline
July–December 2020 timeline
2021 timeline
London
COVID-19 local lockdown regulations in England
First COVID-19 tier regulations in England
Northern Ireland
2020 timeline
2021 timeline
Scotland
2020 timeline
2021 timeline
Wales
2020 timeline
2021 timeline
Crown dependencies
Isle of Man
Jersey
Guernsey
Overseas territories
Akrotiri and Dhekelia
British Indian Ocean Territory
Gibraltar
response
Eastern
Belarus
timeline
Kazakhstan
Moldova
Gagauzia
Transnistria
Russia
timeline
government responses
political impact
Crimea
Sevastopol
Turkey
timeline
Ukraine
Donetsk
Luhansk
Western Balkans
Albania
Bosnia and Herzegovina
Kosovo
Montenegro
North Macedonia
Serbia
timeline
statistics
European Union
Austria
Belgium
Bulgaria
Croatia
timeline
Cyprus
Northern Cyprus
Czech Republic
Denmark
Faroe Islands
Estonia
Finland
Åland
France
Guadeloupe
French Guiana
Réunion
Martinique
Mayotte
Normandy
Saint Martin
Germany
North Rhine-Westphalia
government response
Greece
Hungary
Ireland
timeline
January–June 2020
July–December 2020
January–June 2021
July–December 2021
economic impact
social impact
vaccination
Italy
lockdown
timeline
Latvia
Lithuania
Luxembourg
Malta
timeline
Netherlands
Poland
Portugal
Romania
timeline
Slovakia
Slovenia
Spain
timeline
Asturias
Canary Islands
Ceuta
Community of Madrid
Melilla
Sweden
timeline
government response
Operation Gloria
EFTA countries
Iceland
Liechtenstein
Norway
Svalbard
Switzerland
Microstates
Andorra
Monaco
San Marino
Vatican City
NorthAmericaAtlantic
Bermuda
Greenland
Saint Pierre and Miquelon
Canada
timeline
economic impact
federal aid
vaccination
by province
military response
Atlantic Bubble
Alberta
timeline
British Columbia
Manitoba
New Brunswick
Newfoundland and Labrador
Northwest Territories
Nova Scotia
Nunavut
Ontario
timelines
2020
2021
2022
Ottawa
Peel Region
Toronto
York Region
Prince Edward Island
Quebec
Montreal
boroughs
timeline
Saskatchewan
timeline
Yukon
Caribbean
Antigua and Barbuda
Bahamas
Barbados
British Overseas Territories
Anguilla
British Virgin Islands
Cayman Islands
Montserrat
Turks and Caicos Islands
response
Cuba
Guantanamo Bay Naval Base
Dominica
Dominican Republic
Dutch Caribbean
Aruba
Curaçao
Sint Maarten
Caribbean Netherlands
Bonaire
Saba
Sint Eustatius
French West Indies
Guadeloupe
Martinique
Saint Barthélemy
Saint Martin
Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Trinidad and Tobago
timeline
US insular areas
Puerto Rico
U.S. Virgin Islands
Central America
Belize
Costa Rica
El Salvador
Guatemala
Honduras
Mexico
timeline
Nicaragua
Panama
United States
timeline
2020
2021
impact
social
economic
2021 hospital crisis
responses
federal government
state and local governments
California government response
New York government response
Texas government response
Eastern States Multi-state Council
Midwest Governors Regional Pact
Western States Pact
Trump administration communication
Alabama
Alaska
American Samoa
Arizona
Navajo Nation
Arkansas
California
timeline
S.F. Bay Area
Colorado
Connecticut
Delaware
Florida
Georgia
Guam
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
timeline
Massachusetts
timeline
Boston
timeline
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
timeline
New Hampshire
New Jersey
New Mexico
New York
New York City
timeline
North Carolina
North Dakota
Northern Mariana Islands
Ohio
Columbus
Oklahoma
Oregon
Portland
Pennsylvania
Philadelphia
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
timeline
Austin
U.S. Virgin Islands
Utah
Vermont
Virginia
Washington
Washington, D.C.
White House
West Virginia
Wisconsin
Wyoming
Oceania
American Samoa
Cook Islands
Easter Island
Federated States of Micronesia
Fiji
timeline
French Polynesia
Guam
Hawaii
Kiribati
Marshall Islands
New Caledonia
New Zealand
timeline
2020
2021
government response
social impact
managed isolation
Norfolk Island
Northern Mariana Islands
Palau
Papua New Guinea
Bougainville
Samoa
Solomon Islands
Tonga
Vanuatu
Wallis and Futuna
Australia
timeline
2020
2021
January–June
July–December
Australian Capital Territory
New South Wales
Northern Territory
Queensland
South Australia
Tasmania
Victoria
Western Australia
SouthAmerica
Argentina
timeline
statistics
human rights
Bolivia
Brazil
São Paulo
Chile
statistics
Easter Island
Colombia
Ecuador
Falkland Islands
French Guiana
Guyana
Paraguay
Peru
Cusco
Suriname
Uruguay
timeline
2020
2021
Venezuela
Others
Antarctica
Cruise ships
Diamond Princess
Grand Princess
Naval ships
Charles de Gaulle
USS Theodore Roosevelt
ImpactsCulture andentertainment
Arts and cultural heritage
References in popular culture
Cinema
films affected
Disney
Education
homeschooling
by country
Ghana
Ireland
United Kingdom
exam grading controversy
United States
Fashion industry
Music industry
Performing arts
Sports
By country
Ireland
Philippines
By sport
association football
combat sports
cricket
disc golf
Gaelic games
gridirion football (NCAAF, NFL, and CFL)
motorsport
NBA
rugby league
Television
U.S.
programs affected
Video games
Society and rights
Social
social media
stigma
COVID-19 parties
Children
foster care in the U.S.
Gender
Healthcare workers
Hospitals
ICU capacity
Human rights
Legal
abortion in the U.S.
crime
crime in Ireland
domestic violence
prisons
U.S. immigration detention
LGBT community
African-American communities
Native American communities
Long-term care facilities
Public transport
Religion
Catholic Church
Hajj
Strikes
Xenophobia and racism
Economic
Aviation
Airlines
Cannabis industry
Charitable activity
COVID-19 scams
COVID-19 recession
Economic
Canada
India
Ireland
COVID-19 Pandemic Unemployment Payment
Malaysia
New Zealand
U.K.
U.S.
Financial markets
Food industry
meat industry in Canada
meat industry in the U.S.
restaurant industry in the U.S.
Global stock market crash
Global supply chain
Hospitals
Mink farming
Oil price war
Retail
Great Resignation
Tourism
Travel restrictions
Information
Journalism
Media coverage
Misinformation
Governments
China
Philippines
United States
Ivermectin
Plandemic
Wikipedia's response
Politics
National responses
Legislation
Protests
Canada
Italy
Germany
Idar-Oberstein shooting
the Netherlands
New Zealand
Serbia
United Kingdom
United States
Open the States
International relations
Aid
Italy
Moldovan–Romanian collaboration
Respirator diplomacy of Taiwan
European Union
Ireland
Malaysia
Language
Doomscrolling
Flattening the curve
Living with COVID-19
Long-hauler
Quarantini
Social distancing
Superspreader
Zero-COVID
Zoom
Zoom towns
Others
Animals
Anthropause
Environment
Military
Science and technology
Food security
Health issuesMedical topics
Transmission
Symptoms
Cancer
Skin manifestations
Long COVID
Mental health
neurological, psychological and other mental health outcomes
Pregnancy
Non-COVID-19–related health issues
Shortages
Raise the line
Rehabilitation
Unproven medical methods
Testing andepidemiology
Disease testing
Breathalyzer
Operation Moonshot
Test to Release
UK Rapid Test Consortium
AbC-19 rapid antibody test
Rapid antigen test
investigations into the origins
lab leak theory
Surveillance
Death rates by country
Datasets
Apps
careFIJI
COVID Alert (Canada)
COVID AlertSA (South Africa)
COVIDSafe
COVID Tracker Ireland
Coronavirus Australia
Aarogya Setu
NZ COVID Tracer
TraceTogether
BlueTrace
Decentralized Privacy-Preserving Proximity Tracing
NHS COVID-19
MySejahtera
SwissCovid
TCN Protocol
Exposure Notification
COVID Symptom Study
Test, Trace, Protect
NHS Test and Trace
Undercounting COVID-19 deaths
Use and development of software
Prevention
Social distancing
Face masks
Mask refusal
United States
Flattening the curve
Zero-COVID
Workplace hazard controls
Lockdowns
Evacuations
International aid
Safe Hands Challenge
COVID fatigue
Great Barrington Declaration
Chloroquine and hydroxychloroquine
VaccinesTopics
Development
Clinical research
Authorizations
Deployment
Post-vaccination complications
Operation Warp Speed (U.S.)
Vaccine passports
Vaccine card
Misinformation and hesitancy
Deaths of anti-vaccine advocates
US
AuthorizedDNA
ZyCoV-D
Inactivated
Chinese Academy of Medical Sciences
CoronaVac
Covaxin
COVIran Barekat
CoviVac (Russia)
FAKHRAVAC
Minhai
QazCovid-in
Sinopharm BIBP
Sinopharm WIBP
TurkoVac
RNA
Moderna
Pfizer–BioNTech
Subunit
Abdala
Corbevax (Bio E COVID-19)
COVAX-19
EpiVacCorona
MVC
Novavax
Razi Cov Pars
Sinopharm CNBG
Soberana 02
Soberana Plus
ZF2001 (Zifivax)
Viral vector
Convidecia
Janssen
Oxford–AstraZeneca
Sputnik V
Sputnik Light
In trialsAttenuated
COVI-VAC (United States)
DNA
AG0302-COVID‑19
GX-19
Inovio
Inactivated
KD-414
NDV-HXP-S
Valneva
RNA
ARCT-021
ARCT-154
Bangavax
CureVac (terminated)
HGC019
mRNA-1283
PTX-COVID19-B
Sanofi–Translate Bio (terminated)
Stemirna COVID-19 vaccine
Walvax
Subunit
202-CoV
AKS-452
EuCorVac-19
GBP510
IVX-411
Nanocovax
Noora
ReCOV
Sanofi–GSK
S-268019
SCB-2019
SCTV01C
UB-612
V-01
V451 (terminated)
Vabiotech
West China Hospital
Zhongyianke Biotech–Liaoning Maokangyuan Biotech‎
Viral vector
AdCLD-CoV19
BBV154
BriLife
COH04S1
DelNS1-2019-nCoV-RBD-OPT
GRAd-COV2
ImmunityBio
INNA-051
NDV-HXP-S
Vaxart COVID-19 vaccine
Virus-like particles
ABNCoV2
CoVLP
LYB001
MigVax-101
VBI-2902
Deploymentby locationAfrica
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Cameroon
Chad
Comoros
Democratic Republic of the Congo
Djibouti
Egypt
Equatorial Guinea
Eswatini
Ghana
Morocco
Nigeria
Senegal
South Africa
Zimbabwe
Asia
Bangladesh
Bhutan
Mainland China
India
Indonesia
Iran
Israel
Japan
Kazakhstan
Malaysia
Nepal
Philippines
Russia
Singapore
South Korea
Sri Lanka
Taiwan
Thailand
Turkey
United Arab Emirates
Vietnam
Europe
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Denmark
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Moldova
Norway
Portugal
Romania
Russia
Spain
Sweden
Switzerland
Ukraine
United Kingdom
North America
Canada
Quebec
Cuba
Haiti
Mexico
United States
mandates
Oceania
Australia
Fiji
New Zealand
South America
Argentina
Brazil
Colombia
Peru
Others
Antarctica
Treatment
Drug development
Drug repurposing research
Dexamethasone
Baricitinib
RECOVERY Trial (UK)
Solidarity trial (WHO)
Open-source ventilator
Extracorporeal membrane oxygenation
Monoclonal antibodies
Bamlanivimab/etesevimab
Bamlanivimab
Etesevimab
Casirivimab/imdevimab
Regdanvimab
Sarilumab
Sotrovimab
Tocilizumab
Small molecule antivirals
Broad-spectrum
Remdesivir
Molnupiravir
Variants
Alpha
Beta
Gamma
Delta
Epsilon
Zeta
Eta
Theta
Iota
Kappa
Lambda
Mu
Omicron
Timeline
Cluster 5
Lineage B.1.617
Lineage B.1.640.2
Variant of concern
InstitutionsHospitals andmedical clinicsMainland China
Central Hospital of Wuhan
Dabie Mountain Regional Medical Centre
Fangcang hospitals
Huoshenshan Hospital
Leishenshan Hospital
Xinjia Express Hotel
Wuhan Jinyintan Hospital
Others
Hospital ships
Canberra Coronavirus Field Hospital (Australia)
Hospital El Salvador
SevenHills Hospital (India)
Kemayoran Athletes Village (Indonesia)
Pyongyang General Hospital (North Korea)
Malaysia Agro Exposition Park Serdang (Malaysia)
Mega Ligtas COVID Centers (Philippines)
Kandakadu Treatment and Rehabilitation Centre (Sri Lanka)
Sancaktepe Prof. Dr. Feriha Öz Emergency Hospital (Turkey)
Yeşilköy Prof. Dr. Murat Dilmener Emergency Hospital (Turkey)
COVID-19 hospitals in the United Kingdom
Dragon's Heart Hospital (Wales)
NHS Louisa Jordan (Scotland)
NHS Nightingale Hospitals (England)
Birmingham
London
North East
North West
Yorkshire and the Humber
OrganizationsGlobal
Coalition for Epidemic Preparedness Innovations
Coronavirus Tech Handbook
COVID-19 Solidarity Response Fund
Covid Watch
EcoHealth Alliance
International Committee on Taxonomy of Viruses
Joint Committee on Vaccination and Immunisation
MusiCares COVID-19 Relief Fund
Pasteur Institute
in Cambodia
UN COVID-19 Supply Chain Task Force (WHO)
United Nations
resolutions
World Health Organization
By location
Africa Centres for Disease Control and Prevention (African Union)
National Cabinet (Australia)
National COVID-19 Commission Advisory Board (Australia)
COVID-19 Immunity Task Force (Canada)
COVID-19 Supply Council (Canada)
ScienceUpFirst (Canada)
Wuhan Institute of Virology (China)
PREPARE (European Union)
Ghana Infectious Disease Centre (Ghana)
Department of Health (Hong Kong)
National Expert Group on Vaccine Administration for COVID-19 (India)
PM CARES Fund (India)
SAARC COVID-19 Emergency Fund (India)
COVID-19 Response Acceleration Task Force (Indonesia)
National Public Health Emergency Team (Ireland)
Novel Coronavirus Expert Meeting (Japan)
Korea Disease Control and Prevention Agency (South Korea)
Crisis Preparedness and Response Centre (Malaysia)
Defeat COVID-19 Ad Hoc Committee (Philippines)
Inter-Agency Task Force for the Management of Emerging Infectious Diseases (Philippines)
National Institute for Communicable Diseases (South Africa)
Central Epidemic Command Center (Taiwan)
Taiwan Centers for Disease Control (Taiwan)
Coronavirus Scientific Advisory Board (Turkey)
COVID-19 Genomics UK Consortium (United Kingdom)
Imperial College COVID-19 Response Team (United Kingdom)
Independent SAGE (United Kingdom)
Joint Biosecurity Centre (United Kingdom)
Vaccine Taskforce (United Kingdom)
Artist Relief (United States)
COVID-19 Advisory Board (United States)
Great American Economic Revival Industry Groups (United States)
White House Coronavirus Task Force (United States)
White House COVID-19 Response Team (United States)
GACH (Uruguay)
PeopleMedicalprofessionals
Ai Fen
Corona Rintawan
Li Wenliang
Liu Wen
Xie Linka
Zhang Wenhong
Researchers
Awang Bulgiba Awang Mahmud
Roberto Burioni
Chen Wei
Kizzmekia Corbett
Andrea Crisanti
Peter Daszak
Christian Drosten
Neil Ferguson
Dale Fisher
George F. Gao
Azra Ghani
Sarah Gilbert
Guan Yi
Kentaro Iwata
Katalin Karikó
Matt Keeling
Trudie Lang
Li Lanjuan
W. Ian Lipkin
Ma Xiaowei
Shabir Madhi
Allison McGeer
Camilla Rothe
Shi Zhengli
Moncef Slaoui
Mike Tildesley
John Todd
Wang Chen
Wang Guangfa
Drew Weissman
Yuen Kwok-yung
Zeng Guang
Zhang Jixian
Zhang Yongzhen
Zhong Nanshan
OfficialsWHO
Tedros Adhanom (Director-General of the WHO)
Bruce Aylward (Team lead of WHO-China COVID-19 mission)
Maria Van Kerkhove (Technical Lead for COVID-19 response)
Michael J. Ryan (Executive Director of the WHO Health Emergencies Programme)
By location
Frank Atherton (Wales)
Ashley Bloomfield (New Zealand)
Catherine Calderwood (Scotland)
Chang Shan-chwen (Taiwan)
Anutin Charnvirakul (Thailand)
Chen Shih-chung (Taiwan)
Kenneth Chuang Yin-ching (Taiwan)
Victor Costache (Romania)
Fabrizio Curcio (Italy)
Carmen Deseda (Puerto Rico)
Jaap van Dissel (the Netherlands)
Christian Drosten (Germany)
Francisco Duque III (Philippines)
Anthony Fauci (United States)
Francesco Paolo Figliuolo (Italy)
Graça Freitas (Portugal)
Henrique Gouveia e Melo (Portugal)
Matt Hancock (United Kingdom)
Hamad Hasan (Lebanon)
Greg Hunt (Australia)
Tony Holohan (Ireland)
Jeong Eun-kyeong (South Korea)
Fahrettin Koca (Turkey)
Li Keqiang (China)
Hugo López-Gatell Ramírez (Mexico)
Michael McBride (Northern Ireland)
Oriol Mitjà (Andorra)
Zweli Mkhize (South Africa)
Doni Monardo (Indonesia)
Alma Möller (Iceland)
Saeed Namaki (Iran)
Ala Nemerenco (Moldova)
Nguyễn Thanh Long (Vietnam)
Noor Hisham Abdullah (Malaysia)
Ali Pilli (Northern Cyprus)
Daniel Salinas (Uruguay)
Jérôme Salomon (France)
Fernando Simón (Spain)
Gregor Smith (Scotland)
Su Ih-jen (Taiwan)
Łukasz Szumowski (Poland)
Theresa Tam (Canada)
Anders Tegnell (Sweden)
Þórólfur Guðnason (Iceland)
Sotiris Tsiodras (Greece)
Harsh Vardhan (India)
Víðir Reynisson (Iceland)
Carla Vizzotti (Argentina)
Vlad Voiculescu (Romania)
Chris Whitty (United Kingdom)
Lawrence Wong (Singapore)
Jeffrey Zients (United States)
Others
Chen Qiushi
Brett Crozier
Fang Bin
Fang Fang
Joseph Ashitey Hammond
Li Zehua
Captain Tom Moore
Qiu Menghuang
Ren Zhiqiang
DeathsListData (templates)Global
Cases, deaths, recoveries by country
Tests, cases, tests per capita, cases per capita by country
Tests, cases, tests per capita, cases per capita by country subdivision
WHO situation reports
cases
January 2020
February 2020
March 2020
April 2020
May 2020
June 2020
July 2020
August 2020
September 2020
October 2020
November 2020
December 2020
January 2021
February 2021
April 2021
May 2021
June 2021
July 2021
deaths
World map by countries: confirmed per capita
China
Hospital beds by country
Lockdowns
Africa
Algeria
chart
Angola
chart
Benin
chart
Botswana
chart
Burkina Faso
chart
Burundi
chart
Cameroon
chart
Comoros
chart
Egypt
chart
Eswatini
chart
Ethiopia
chart
Ghana
chart
Ivory Coast
chart
Kenya
chart
Libya
chart
Malawi
chart
Mali
chart
Mauritania
chart
Mauritius
chart
Morocco
chart
Mozambique
chart
Namibia
chart
Nigeria
chart
São Tomé and Príncipe
chart
Senegal
chart
Seychelles
chart
Sierra Leone
chart
South Africa
chart
South Sudan
chart
Sudan
chart
Tanzania
chart
Togo
chart
Tunisia
chart
Uganda
chart
Zambia
chart
Zimbabwe
chart
Americas
Argentina
chart
Bolivia
chart
Brazil
chart
Canada
by province
chart
vaccinations by province
Chile
by commune
chart
Colombia
chart
Costa Rica
chart
Cuba
chart
Dominican Republic
chart
Ecuador
chart
El Salvador
chart
Guatemala
chart
Haiti
chart
Honduras
chart
Mexico
chart
Nicaragua
chart
Panama
chart
Paraguay
chart
Peru
chart
United States
by state
chart
Uruguay
chart
Venezuela
chart
Asia
Afghanistan
chart
Armenia
chart
Azerbaijan
chart
Bahrain
chart
Bangladesh
chart
Bhutan
chart
summary
Brunei
chart
Cambodia
chart
summary
Mainland China
aggregate
chart
confirmed per capita
areas of lockdown
Cyprus
chart
Egypt
chart
Georgia
chart
Hong Kong
chart
India
chart
summary
Indonesia
chart
Iran
chart
Iraq
chart
Israel
chart
Japan
chart
Jordan
chart
Kazakhstan
chart
South Korea
chart
vaccinations charts
Kuwait
graph
chart
Kyrgyzstan
chart
Laos
Lebanon
chart
Malaysia
chart
Myanmar
chart
Nepal
chart
by district
PCR tests
Oman
chart
Pakistan
chart
Palestine
chart
Philippines
chart
areas of quarantine
vaccinations chart
Qatar
chart
Russia/North Asia
by federal subject
chart
Saudi Arabia
chart
Singapore
chart
Sri Lanka
chart
Syria
chart
Taiwan
chart
Tajikistan
chart
Thailand
chart
summary
Turkey
by province
chart
United Arab Emirates
chart
Uzbekistan
chart
Vietnam
chart
Yemen
chart
Europe(chart)
Albania
chart
Austria
chart
Belarus
chart
Belgium
chart
Bosnia and Herzegovina
chart
Bulgaria
chart
Croatia
chart
Cyprus
chart
Czech Republic
chart
Denmark
chart
Estonia
chart
Faroe Islands
chart
Finland
chart
France
chart
Germany
chart
Greece
chart
Hungary
chart
Iceland
chart
Ireland
chart
Italy
chart
vaccinations chart
Kosovo
chart
Latvia
chart
Lithuania
chart
Luxembourg
chart
Malta
chart
Moldova
chart
Monaco
chart
Montenegro
chart
Netherlands
chart
North Macedonia
chart
Norway
chart
Poland
chart
Portugal
chart
Romania
chart
Russia
by federal subject
chart
San Marino
chart
Serbia
chart
Slovakia
by region
chart
Slovenia
chart
Spain
chart
Asturias
Community of Madrid
Sweden
chart
Switzerland
chart
Turkey
by province
chart
Ukraine
chart
Donetsk People's Republic
Luhansk People's Republic
United Kingdom
Scotland
chart
vaccinations chart
daily
by nation
Vatican City
chart
Oceania
Australia
chart
by state/territory
Fiji
chart
French Polynesia
chart
New Caledonia
chart
New Zealand
chart
Papua New Guinea
chart
Solomon Islands
chart
Others
Cruise ships
Diamond Princess

 COVID-19 portal
 Category

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portals:MedicineVirusesCOVID-19





